Tata Laksana Lambert Eaton Myasthenic Syndrome


  • Marcellinus Michael Leonard Mardiono RS Gading Pluit
  • Widyawati Suhendro




Lambert-Eaton myasthenic syndrome, neuromuscular, small cell lung carcinoma


Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular junction disorder resulting from a paraneoplastic or autoimmune reaction. More than half LEMS cases are associated with small cell lung carcinoma (SCLC). The main clinical manifestation is muscle weakness. The pathophysiology is due to the generation of the autoantibodies against voltage-gated calcium channels (VGCCs) on presynaptic nerve terminals leading to a decrease in neurotransmitter acethylcholine (ACh). Various treatments such as tumor treatments, immunomodulatory, and symptomatic treatment have been studied, but further research is needed.


Download data is not yet available.

Author Biography

Widyawati Suhendro



Jayarangaiah A, Kariyanna PT. Lambert eaton myasthenic syndrome [Internet]. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507891/

Pascuzzi RM, Bodkin CL. Myasthenia gravis and Lambert-Eaton myasthenic syndrome: New developments in diagnosis and treatment. Neuropsychiatr Dis Treat. 2022;18:3001–22.

Raja SM. Lambert-Eaton myasthenic syndrome and botulism. Continuum (Minneap Minn). 2022;28(6):1596-614.

Yoon CH, Guha JO, Smith A, Buschur P. Amifampridine for the management of Lambert-Eaton myasthenic syndrome: A new take on an old drug. Sagepub 2020;54(10):57-63.

Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton myasthenic syndrome. Neurol Clin. 2018;36(2):379–94.

Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008;70:924–8

Linguist S, Stangel M. Update on treatment options for Lambert–Eaton myasthenic syndrome: Focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341-9. doi: 10.2147/NDT.S10464.

Antoine JC, Camdessanche JP. Treatment options in paraneoplastic disorders of the peripheral nervous system. Curr Treat Options Neurol. 2013;15(2):210-23. doi: 10.1007/s11940-012-0210-9.

Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JGC, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert–Eaton myasthenic syndrome: A randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009;86:44–8

Verschuuren JJ, Wirtz PW, Titulaer MJ, Willems LN, van Gerven J. Available treatment options for the management of Lambert–Eaton myasthenic syndrome. Expert Opin Pharmacother. 2006;7:1323–36

McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989;321:1567–71

Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011;(2):CD003279

Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert–Eaton myasthenic syndrome. Neurology 2000;54:603–7

Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: From clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098–107

Raust JA, Goulay-Dufay S, Le Hoang MD, Pradeau D, Guyon F, Do B. Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products. J Pharm Biomed Anal. 2007;43:83–8

Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, Blanco JM, et al. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve 2016;53(5):717–25

Anderson C, Guidon A, Khan F, Thomas A, Riehle C, Hehir M, et al. Case report of Lambert Eaton myasthenic syndrome in a patient with small cell lung cancer on immune checkpoint inhibitor therapy. Burlington, USA: OBM Neurobiology; 2021.

Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678–83

Illa I IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: Current status. J Neurol. 2005;252(Suppl 1):I14–8

Maddison P, Lang B, Mills K, Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatr 2001;70(2):212–7.

Chalk CH, Murray NM, Newsome-Davis J, O'Neill JJH, Spiro SG. Responses of the Lambert-Eason myasthenic syndrome to treatment of associated small-cell lung cancer. Neurology 1990;40:1552–6




How to Cite

Mardiono, M. M. L., & Suhendro , W. (2023). Tata Laksana Lambert Eaton Myasthenic Syndrome . Cermin Dunia Kedokteran, 50(11), 611–615. https://doi.org/10.55175/cdk.v50i11.676